Nanosuspensions: A Promising Drug Delivery Systems
DOI:
https://doi.org/10.37285/ijpsn.2009.2.4.1Abstract
One of the critical problems associated with poorly soluble drugs is low bioavailability and or erratic absorption. The problem is even more complex for drugs such as itraconazole and Carbamazepine (belonging to BCS CLASS II) as they are poorly soluble in both aqueous and organic media, and for those drugs having a log P value of 2. There are number of formulation approaches to resolve the problems of low solubility and low bioavailability. But all those have some limitations and hence have limited utility in solubility enhancement. Nanotechnology can be used to resolve these problems associated with conventional approaches. Nanotechnology is defined as the science and engineering carried out in the nanoscale that is 10-9 meters. Nanosuspensions consist of the pure poorly water-soluble drug without any matrix material suspended in dispersion. A nanosuspension not only solves the problems of poor solubility and bioavailability but also alters the pharmacokinetics of drug and thus improves drug safety and efficacy
Downloads
Metrics
Keywords:
Nanotechnology, Nanosuspensions, drug delivery, bioavailability
Downloads
Published
How to Cite
Issue
Section
References
Challa R, Ahuja A, Ali J and Khar RK, Cyclodextrins in drug delivery: an updated Review, AAPS Pharm.Sci.Tech., 6(2): 329-357 (2005)
Cornelia M. Keck and Rainer H. Muller, Drug nanocrystals of poorly soluble drugs produced by high-pressure homogenisation, Eur. J. Pharm.Biopharm, 62: 3–16 (2006)
Elaine Merisko-Liversidge, Gary G. Liversidge and Eugene R.Cooper, Nanosizing: A formulation approach for poorly water-soluble compounds, Eur.J.Pharm.Sci, 18: 113-120 (2003)
Friedrich S, Reichl CC and Muller G, Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS), Int.J.Pharmaceutics, 305: 167-175 (2005)
Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ, Applications of microemulsion based drug delivery system, Cur. Dr. Del, 3(3): 3, 267-273(2006)
Jan Moschwitzer, Georgr Achleitner, Herberk Pomper, Rainer H.Muller, Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension, Eur. J. Pharm. Biopharm, 58: 615-619 (2004)
Krause KP, and Muller RH, Production and characterization of highly concentrated nanosuspensions by high pressure homogenisation, Int.J.Pharm, 214: 21-24 (2001)
Krause KP, Kayser O, Mader K, Gust R and Muller RH, Heavy metal intamination of nanosuspensions produced by high-pressure homogenisation, Int. J. Pharm, 196: 169–172 (2000)
Lei G, Dianrui Z, Minghui C, Cunxian D, Wenting D, Lejiao J and Wenfa Z, Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions, Int.J.Pharmaceutics, 355: 321-327 (2008)
Leuner C and Dressman J, Improving drug solubility for oral delivery using solid dispersions, Eur.J.Pharm.Biopharm, 50(1): 47-60 (2000)
Mahesh V.Chaubal, Application of formulation technologies in lead candidate selection and optimization, Drug Dis.Today, 9(14): 603-609 (2004)
Mehnert W and Mader K, Solid lipid nanoparticles: Production, characterization and applications, Adv.Drug Deliv. Rev. 47(2-3): 165-196 (2000)
Mitra Mosharraf, Christer Nystrom, The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs, Int.J. Pharm., 122: 35-47 (1995)
Montasser, Fessi H, and Coleman AW, Atomic force microscopy imaging of novel type of polymeric colloidal nanostructures, Eur. J.Pharm.Biopharm, 54: 281–284 (2002)
Muller RH, Gohla S, Dingler A and Schneppe T, Large-scale production of solid-lipid nanoparticles (SLN) and nanosuspension(Dissocubes), In D.Wise (Ed.) Handbook of Pharmaceutical Controlled Release Technology, 359-375(2000)
Muller RH and Jacobs C, Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability, Int.J.Pharmaceutics, 237: 151-161 (2002)
Muller RH, Jacobs C, Kayser O, Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future, Ad.Drug Del.Rev, 47: 3-19 (2001)
Muller RH and Junghanns JAH, Drug Nanocrystals/Nanosuspensions for the Delivery of Poorly Soluble Drugs, Nanoparticulates as Drug carriers, 307(2006)
Muller RM, Bohm BHL and Grau J, Nanosuspensions : a formulation approach for poorly soluble and poorly bioavailable drugs, In D.Wise (Ed.) Handbook of Pharmaceutical Controlled Release Technology, 345-357(2000)
Patravale VB, Abhijit A.Date and Kulkarni RM, Nanosuspensions: a promising drug delivery strategy, J.Pharm.Pharcol, 56: 827-840 (2004)
Riaz M., Stability and uses of liposomes, Pak.Pharm.Sci, 8( 2): 69-79 (1995)
Siham Ben Z, Alain A, Marc M and Stephane G, Comparison of nanosuspensions and hydroxypropyl-b-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice, Eur.J.Pharmaceutics and Biopharm.,70: 649-656 (2008)
True L.Rogers, Ian B. Gillespie, James E. Hitt, Kevin L.Fransen, Clindy A. Crowl, Chritoper J.Tucker, et.al. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly soluble drugs, Pharm.Res, 21: 11( 2004)
